Sana Biotechnology (SANA) awards RSUs and stock options to officer

Rhea-AI Filing Summary

Sana Biotechnology, Inc. reported that officer Susan D. Wyrick acquired new equity awards. She received 45,833 restricted stock units and a stock option for 206,250 shares on March 5, 2026, both at a grant price of $0.00 per unit or option.

The restricted stock units vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030, conditioned on continued service with Sana. The stock option vests as to 25% of the underlying shares on March 5, 2027 and then in 36 equal monthly installments, also requiring continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Wyrick Susan D.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	45,833	$0.00	--
Grant/Award	Stock Option (Right to Buy)	206,250	$0.00	--

Holdings After Transaction: Restricted Stock Units — 45,833 shares (Direct); Stock Option (Right to Buy) — 206,250 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wyrick Susan D.

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/05/2026		A		45,833		(2)	(2)	Common Stock	45,833	$0.00	45,833	D
Stock Option (Right to Buy)	$3.41	03/05/2026		A		206,250		(3)	03/04/2036	Common Stock	206,250	$0.00	206,250	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

2. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

3. The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Remarks:

SVP, Finance and Accounting and Principal Accounting Officer

	/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SANA report for Susan D. Wyrick?

Sana Biotechnology, Inc. reported equity grants to officer Susan D. Wyrick. She received 45,833 restricted stock units and a stock option for 206,250 shares on March 5, 2026, both granted at $0.00 per unit or option.

How many restricted stock units did Susan D. Wyrick receive at SANA?

Susan D. Wyrick was granted 45,833 restricted stock units at Sana Biotechnology, Inc. Each unit represents a contingent right to receive one share of Sana common stock, subject to the disclosed vesting schedule and her continued service with the company.

What are the vesting terms for SANA’s restricted stock units granted to Susan D. Wyrick?

The 45,833 restricted stock units vest in four equal annual installments. Vesting occurs on March 5 of 2027, 2028, 2029 and 2030, provided Ms. Wyrick continues serving Sana as an employee, consultant, director or officer through each vesting date.

What stock option grant did Sana Biotechnology (SANA) award to Susan D. Wyrick?

Sana Biotechnology granted Susan D. Wyrick a stock option for 206,250 shares. The option was awarded on March 5, 2026 at a grant price of $0.00 per option, with a multi-year vesting schedule tied to continued service.

How does the stock option granted to Susan D. Wyrick at SANA vest over time?

The stock option vests 25% on March 5, 2027, then monthly. After the initial 25% cliff, the remaining underlying shares vest in 36 equal monthly installments, contingent on Ms. Wyrick’s continuous service with Sana Biotechnology through each vesting date.

Does the Form 4 for SANA show buying or selling of shares by Susan D. Wyrick?

The Form 4 shows equity award acquisitions, not open-market buying or selling. All reported transactions are coded as grants or awards of restricted stock units and stock options, with no recorded sales or purchases in the market.